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SEVRAGE RAPIDE DE LA MÉTHADONE ASSISTÉ PAR LA 
NALTREXONE: UNE ÉTUDE PILOTE 
Rapport de Synthèse 
Un sevrage lent comme méthode élective pour l'intenuption de la méthadone est coûteux en termes 
de temps, le plus souvent associé à un taux élevé d'abandon. 
Bien que les méthodes ultrarapides de désintoxication des opiacés aient gagné en popularité 
récemment, elles sont chères et posent les problèmes spécifiques liés aux patients traités par la 
méthadone. 
Méthodologie: ont été inclus dans l'étude dix patients en traitement de substitution avec de la 
méthadone. La dernière dose de méthadone a été administrée le matin même du jour de l'admission, 
en préalable à l'hospitalisation. 
Les médicaments suivants ont été administrés le jour suivant l'admission: 
ondansetron 36mg, ranitidine 40mg, loperamide 8m., clonazepam 4m., promazine JOOmg, 
metoclopramide 70mg, naltrexone 50mg. 
L'échelle objective de sevrage des opiacés (Objective Opiate Withdrawal Sea le) a été appliquée au 
deuxième, troisième et quatrième jour d'hospitalisation, deux fois par jour, à 8h00 et 18h00. Un 
suivi a été réalisé sous la forme d'entretiens téléphoniques pendant une semaine, respectivement six 
mois après la date de sortie de l'hôpital, faisant suite à la désintoxication. Un autre entretient 
téléphonique a été réalisé dans les six mois suivant le "post-sevrage", avec pour objectif 
d'investiguer la continuité du traitement, une éventuelle rechute dans l'abus de drogues et une 
possible réintroduction de la méthadone. 
Résultats: nous avons pu déterminer quatre groupes de symptômes, sur la base d'une observation de 
trois jours d'évolution: 1) Les signes typiques du syndrome de sevrage de retrait des opiacés, 
symptôme de froid et chaud, pilo-érection, anxiété caractérisée par une intensité initiale élevée et 
une disparition relativement continue. 2) Hyperactivité neurovégétative caractérisée par une 
intensité initiale élevée et une rapide disparition. 3) Phénomènes neurovégétatifs dont l'intensité 
s'est maintenue durant toute la période d'observation. 4) Contractions musculaires, insomnies et 
anorexie, manque d'appétit, réapparaissant chez ce1iains patients au 2ème et au début du 3ème jour. 
Conclusions: une procédure courte de désintoxication utilisant une dose unique de naltrexone 
s'avère être une méthode alternative valable pour un sevrage de la méthadone. Cette méthode 
semble accélérer et écomier la symptomatologie associée au sevrage. Le cours des symptômes peut 
être interprété comme biphasique. Une première phase de retrait est éminemment caractérisée par 
tous les symptômes typiques eux-mêmes et probablement induits par la naltrexone. La seconde 
phase, pour un plus petit nombre de patients, peut être interprétée comme en corrélation avec une 
concentration de méthadone en diminution significative ultérieurement. 
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Abstract 
Slow downtitration as a methadone discontinuation meth-
od is time-consuming and associated to high dropout rates. 
Whereas ultra-rapid opiate detoxification methods have re-
cently gained some popularity, they are expensive and may 
be associated with particular problems in methadone pa-
tients. ln the present study, a 3-day detoxification procedure 
accelerated with a unique dose of naltrexone was used in 10 
methadone-substituted patients. Whereas the treatment re-
sulted in a shortened withdrawal syndrome, which was sat-
isfactorily controlled by the drugs used, a two-phase course 
was observed, some symptoms reappearing between the 
end of day 2 and the beginning of day 3. The first phase of 
withdrawal symptoms was attributed to the antagonistic ef-
fect of naltrexone, which possibly also improved under the 
weakening of naltrexone. The second phase of withdraw-
al symptoms may be related to falling methadone plasma 
levels. Copyright~) 2007 S. Karger AG, Basel 
Introduction 
The effectiveness of methadone maintenance treat-
ment in reducing heroin use, criminal activity, risk of 
HIV, fatal and non-fatal heroin overdoses, and in improv-
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ing health and social functioning can actually been con-
sidered as well validated [l, 2]. 
However, when it cornes to the decision to stop meth-
adone, many patients experience difficulty in ceasing 
methadone, with completion rates ranging from about 40 
to 100% depending on factors such as staff approval, rate 
of reduction, psychosocial support and medication pro-
vided. 
Different methadone discontinuation strategies have 
been proposed and studied, and al! have their pros and 
cons. One of the most usual methods is the progressive 
downtitration of rnethadone until reaching 0 mg. This 
has sometimes been supported by concomitant symp-
tomatic treatment of withdrawal symptoms with arad-
renergic agonists [3, 4]. Another method is to substitute 
methadone with buprenorphine, and progressively dis-
continue buprenorphine [5-7]. The feasibility of using 
buprenorphine to assist methadone withdrawal may par-
ticularly be complicated by difficulties in transferring 
from methadone to buprenorphine, as this can precipi-
tate withdrawal symptoms. 
The major disadvantage of all slow downtitration 
methods are their time-consuming aspect, and their high 
drop out rates [ 5]. Reducing the duration of detoxification 
treatment has, on the other hand, recently become of ma-
jor interest as shortening of withdrawal by different 
means has increasingly been fourni to be possible without 
important increases in the severity of withdrawal syrnp-
toms. One of the strategies developed with the aim of 
shortening the opiate withdrawal syndrome uses opiate 
antagonists such as naloxone hydrochloride or naltrex-
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Table 1. Treatment protocol 
Time,h Administered drug Dose, mg 
10:00" Ondansetron 36 
Ranitidine 40 
Loperamide 8 
Clonidine 0.3 
Clonazepam 4 
Promazine 100 
11:00 Metoclopramide 20 
Naltrexone 50 
11:40 Metoclopramide 50 
Clonidine 0.3 
"All drugs administered simultane-
ously. 
one to precipitate withdrawal [8]. A particular method 
using an opiate receptor antagonist for opiate detoxifica-
tion is the so-called ultra-rapid opiate detoxification, 
which is usually performed under conditions of general 
anesthesia [9, 10] or profound sedation [11, 12]. Different 
modifications of the techniques have been developed and 
introduced into practice [13, 14]. One major drawback to 
these methods is the need of expensive critical care. Fur-
thermore, safety is also a major issue for these proce-
dures, since cases of death have been reported following 
this procedure [15]. 
Furthermore, man y of the anesthesia procedures used 
in heroin-dependent patients have been found to have 
higher complication rates in methadone patients [16]. 
Moreover methadone patients seem to experience more 
severe withdrawal symptoms, which may be due to the 
lipophilicity, large distribution volume and long half-life 
of methadone. These particularities often make it neces-
sary to modify and complicate the detoxification proce-
dure [16]. 
The majority of trials studying opiate detoxification 
treatments, and especially those examining rapid meth-
ods, did not specifically select for methadone-substitut-
ed patients, while many patients included were with-
drawing from methadone [4, 12, 17-19]. Furthermore, 
several studies describing methadone detoxification 
used methadone mainly to stabilize the opiate dose prior 
to withdrawal and not as substitution treatment [9, 20, 
21]. 
With regard to antagonist-assisted detoxification, the 
antagonist bas usually been maintained over the detoxi-
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fication period [10, 11, 22, 23], and there is no document-
ed clinical experience on the temporary administration 
of antagonists to accelerate the withdrawal process with-
out continuing the administration of the antagonist. 
However, the administration of small doses of antago-
nists may be an interesting approach not only to acceler-
ate withdrawal but possibly also to modify the symptom 
spectrum, and even to reduce symptom intensity as sug-
gested by recent reports [18, 22]. 
The present study was aimed to assess the efficacy and 
tolerability of a 3-day detoxification procedure acceler-
ated with a unique dose of naltrexone in a selected sample 
of methadone-substituted patients for whom the indica-
tion of an urgent detoxification was given. 
Methods 
Setting 
The stucly was carried out at the Psychiatrie Hospital of the 
Canton Neuchâtel, Perreux, Switzerland, which covers a catch-
ment area of 200,000 inhabitants. As a rule drug-dependent pa-
tients are admitted on a voluntary basis. 
The usual method for methadone discontinuation in the can-
ton of Neuchâtel consists of slow downtitration over several weeks 
on an outpatient basis. For man y patients, a several-week program 
in abstinence-centered therapeutic communities is often recom-
mended by treating professionals following the withdrawal of 
methadone. However, one admission criterion of these centers is 
abstinence already at entry into the program, and places are often 
only available at short term. Hence there is a necessity for a rapid, 
simple and short treatment protocol for these patients as a rneans 
of methadone discontinuation allowing them to enter the thera-
peutic community within a few days. 
Trent111e11t Protocol 
The treatment protocol outlined in table 1 was developed by 
shortening the usual clinical protocol by adding a single dose of 
naltrexone. Ali medication was administered orally. 
The last methadone close was aclministerecl the morning of the 
admission clay before admission itself in all patients. Patients en-
tered the unit between 10:00 and 11:00 a.m. During the whole lst 
day ofhospitalization no pharmacological treatment was applied. 
On the 2nd day of hospitalization, the treatments were adminis-
tered as indicated in table 1. On the 3rd day no further drugs were 
administered. 
Pnrticipants 
Methadone patients who were interested in withclrawal from 
methadone maintenance treatment were considered for the study. 
In order to be includecl in the protocol, patients had to be at least 
18 years old, give informed consent, be under methadone substi-
tution for at least 12 months, and without concomitant illegal 
drug consumption for at least 6 months as established by regular 
urine drug screenings. Furthermore, the decision to discontinue 
methadone had to be made jointly by the patient, his treating phy-
sician as well as the responsible physician of the detoxification 
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unit, on the basis of a pre-hospitalization interview which took 
place 2-4 weeks before hospitalization, and during which social, 
professional and familial stability was evaluated. 
The main non-inclusion criteria were serions medical or psy-
chiatrie conditions, pregnancy, and known intolerances to the 
substances usecl in the present protocol. Pinally, patients who 
were also clependent on benzodiazepines, alcohol or cocaïne ac-· 
cording to ICD-10 were excluded. Patients in whom urine screen-
ing revealed recent benzodiazepine use, but for whom no benzo-
diazepine dependence coule! be diagnosed, were included. 
A.ssessment 
Ali patients underwent meclical assessment on admission and 
a urine drug screening was clone in order to assess potential other 
drug consumptions. Furthermore, standard laboratory measure-
ments (full bloocl count, clinical chemistry profile) were per-
formed, and results were available before application of the first 
dose of treatment. Patients with samples positive for opiates ( oth-
er than methadone) were excluded from the study. Diagnoses 
were determined according to ICD-10. 
The Objective Opiate Withdrawal Scale (OOWS) [24] was ap-
plied on the 2nd, 3rd and 4th day of hospitalization, twice a day, 
at 8:00 a.m. and at 6:00 p.m. Blood pressure and pulse rate were 
also measured. The OOWS is an objective scale with 13 observ-
able physical signs of withdrawal. A clinician rates the symptoms 
as being absent (0) or present (1). The maximum score is there-
fore 13. 
In addition the following three items were attached to the stan-
dard OOWS scale: craving, insomnia, and lack of appetite. 
Blood pressure, heart frequency and temperature were as-
sessed twice daily (8:00 a.m. and 6:00 p.m.). As ail values re-
mained within normal ranges during the whole observation pe-
riod, they will not be specifically reported in the results section. 
Pollow-Up 
A follow-up was performed by telephone interview 1 week and 
6 months after discharge. As all patients were transferred to a 
therapeutic community after methadone detoxification, a nurse 
from the corresponding therapeutic community was contacted 
after 1 week to assess possible persistent withdrawal symptoms. 
A further telephone interview at 6 months after withdrawal was 
done which aimed to investi gate retention in treatrnent, relapse in 
drug abuse, and possible reintroduction of methadone. 
Results 
Characterizatio11 of the Patients 
The patient sample consisted of 3 women and 7 men. 
The mean age was 30.0 ± 3.7 (range 25-35) years. Besicles 
the ICD-10 diagnosis of opiate dependence and metha-
done substitution, 3 patients were also diagnosed as hav-
ing borderline personality disorder (ICD-10: F60.31), 1 
patient had a diagnosis of impulsive personality disorder 
(ICD-10: F60.30), and 1 patient had a history ofobsessive-
compulsive disorder (ICD-10: F42.2) and generalized 
anxiety disorder (ICD-10: F41.1). 
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Two patients were treated on admission to the hospital 
with quetiapine, and 1 patient received paroxetine. The 
mean methadone dose at entry was 44.5 ± 38.4 (range 
10-140) mg/day. 
The initial urine drug screening revealed recent am-
phetamine consumption in 1 patient, benzodiazepine in-
take in 5 patients, cannabis consumption in 5 patients, 
and 1 subject had recently consumed cocaine. 
Ejficacy 
The efficacy data are shown in table 2. The symptoms 
are arranged in 4 groups (A-D) according to their evolu-
tion over the 3 days of observation. As only 1 patient pre-
sented with mydriasis during the whole observation pe-
riod, serions doubts about the accuracy of the ratings for 
this item must be raised, and therefore it is not shown in 
table 2. 
Group A symptoms, which contains some of the most 
typical signs of the opiate withdrawal syndrome ( craving, 
hot and cold flashes, piloerection and anxiety), are char-
acterized by a high initial prevalence with most of the 
patients presenting with these symptoms which continu-
ously disappear over the following 3 days. 
Group B symptoms are mainly related to neurovegeta-
tive hyperactivation and are characterized by a high ini-
tial prevalence and rapid disappearance in most pa-
tients. 
Group C symptoms are also linked to neurovegetative 
phenomena, however their prevalence remains low over 
the whole observation period. 
Group D symptoms, such as muscle twitches, insom-
nia and lack of appetite, reappeared in some patients at 
the end of day 2 and the beginning of day 3. Four of the 
5 patients who complained of muscle twitches and pain 
on the morning of day 3 were among the patients who 
presented insomnia the nights before. 
Follow-Up 
One week after dismissal from the unit, i.e. 10 days 
after the beginning of treatment, the responsible nurse of 
the therapeutic community was contacted by telephone 
and interviewed with regard to possible persistent with-
drawal symptoms. Among the 10 patients, 5 presented 
further episodes of aches and 6 had 1 or more nights with 
sleep problems (initial or midnight insomnia). No evi-
dent other withdrawal symptoms were reported. Craving 
seemed to be absent in all patients during the lst week 
after dismissal from our unit, as reported by the nurse. 
With regard to the follow-up at 6 months, 8of10 pa-
tients completed the therapeutic program as planned or 
Camarasa/Khazaal /Besson /Zullino 
Table 2. Evolution of symptoms 
Dayl Day2 Day3 
-------
-------
8:00 h 18:00 h 8:00 h 18:00 h 8:00 h 18:00 h 
Group A 
Craving 7 7 5 3 4 2 
Anxiety 6 6 4 4 3 1 
Hot and co/d flashes 9 6 5 4 5 3 
Piloerection 6 7 4 7 4 2 
Group B 
Tremors 7 3 3 2 0 
R.estlessness 7 3 5 3 2 
Abdominal cramps 8 2 1 2 l 0 
11omiting 4 2 0 0 
Perspiration 4 0 0 
--·--···-----····-·····-··-~---- ···------···----··- ··················---·-·-·-·-·····-· ···········--···--·· 
Group C 
Yaw11i11g 2 3 3 2 0 0 
Lacrimatio11 2 2 2 () () () 
R.hinorrhea 3 2 0 2 2 
Group D 
lviusc/e twitches 3 3 2 4 5 3 
Insomnia 4 3 5 
Lack of appetite 4 3 2 4 2 
Items of the Objective Opiate Withclrawal Scale (OOWS) are given in italics. 
The item mydriasis is not given due to doubts about accuracy of ratings. 
were still in the therapeutic community. Of these 8 pa-
tients, 2 had had at least one consumption episode, 1 pa-
tient abusing alcohol and 1 patient relapsing to heroin. Of 
the 2 patients who did not complete the therapeutic pro-
gram, 1 patient of foreign nationality was expelled from 
Switzerland and therefore the program was interrupted, 
and the other patient dropped out due to a relapse tocan-
nabis and alcohol consumption. This last patient has sub-
sequently received buprenorphine substitution treat-
ment. 
Discussion 
In this pilot study on 10 patients undergoing rapid 
methadone detoxification using a single dose of naltrex-
one, we found the present treatment procedure to shorten 
and satisfactorily confrol the withdrawal syndrome. The 
typical signs of opiate withdrawal, craving, hot and cold 
flashes, piloerection and anxiety, improved continuously 
over the 3 days of observation. 
The course of the symptoms can be interpreted as bi-
phasic. A first withdrawal phase, which is mainly charac-
Naltrexone-Assisted Rapid Methadone 
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terized by all typical withdrawal symptoms, is probably 
naltrexone-induced and can be seen in most patients as 
group A symptoms during the vvhole day l, and as group 
B symptoms on the morning of day 1. In a second phase, 
concerning fewer patients and extending between the 
end of day 2 and the morning of day 3, aches, insomnia, 
and loss of appetite worsened, which can be interpreted 
as being related to the further significantly declining 
methadone concentrations. 
Group B symptoms, mainly related to neurovegetative 
hyperactivation and characterized by a high initial prev-
alence and rapid disappearance, could be related to the 
antagonistic effects of naltrexone which disappeared 
from day 2 onwards due to the short half-life of naltrex-
one and the reappearing effect of the remaining metha-
done concentrations. 
Group D symptoms, muscle twitches, insomnia and 
lack of appetite, which reappeared in some patients at the 
end of day 2 and the beginning of day 3, could be inter-
preted as being related to the fa.lling methadone plasma 
levels, as their beginning coincides with the habitually 
expected beginning of most of the methadone withdraw-
al symptoms. In those patients who complained about 
Eur Addict Res 2007;13:20-24 23 
muscle twitches and pain, insomnia the night before 
seemed to be a premonitory sign. 
Therefore, the present treatment procedure seems to 
shorten the course of some typical opiate withdrawal 
symptoms, to move forward and at the same time shorten 
the neurovegetative hyperactivation associated with 
withdrawal, and therefore represents a promising alter-
native as a methadone detoxification method. A signifi-
cant problem remains the reappearance of s01ne distress-
ing symptoms on day 3, which can be counteracted with 
adequate analgesic co-medications in future treatment 
protocols, for instance with ibuprofen. 
vation biases, as the group B symptoms such as tremor are 
easily recognizable phenomena or likely to be reported by 
the patient such as nausea, whereas group C symptoms 
such as yawning, lacrimation, and rhinorrhea rely com-
pletely on the observation skills of the monitoring nurse. 
Further evident limitations of this pilot study are the open 
treatment conditions, the limited sample size, the limited 
observation duration, and the non-standardized follow-
up, and the lack of biological validation ( e.g. urinanalysis) 
of drug use during the follow-up period. 
The results of this study need to be viewed against their 
methodological limitations. The recorded differences be-
tween the syrnptom groups could have been due to obser-
In conclusion, a short detoxification procedure using 
a single naltrexone dose appears to be a feasible alterna-
tive method for methadone detoxification, and seems to 
accelerate and shorten the withdrawal-associated symp-
tomatology. 
24 
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